Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection
This clinical trial adopts an observational research method to conduct annual follow-up and monitoring of patients receiving treatment with Inaticabtagene Autoleucel Injection after its commercialization, in order to evaluate the delayed adverse events of Inaticabtagene Autoleucel Injection.
| Condition(s) | B-cell Tumors |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This clinical trial adopts an observational research method to conduct annual follow-up and monitoring of patients receiving treatment with Inaticabtagene Autoleucel Injection after its commercialization, in order to evaluate the delayed adverse events of Inaticabtagene Autoleucel Injection. |
| Who can participate | Inclusion Criteria: 1. Agree to sign an informed consent form for long-term follow-up studies. 2. Registered clinical trial patients with different indications for this product who have received at least one infusion of Inaticabtagene Autoleucel Injection in the past, as well as post market commercialized patients. Exclusion Criteria: \- None. |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Juventas Cell Therapy Ltd. |
| Locations | Tianjin, Tianjin Municipality, China |
| Start date | 2024-03-30 |
| NCT ID | NCT06461351 |
| Official listing | https://clinicaltrials.gov/study/NCT06461351 |